Kinase inhibitors types

Akin C. Brockow K. D Ambrosio C. et al Effects of tyrosine kinase inhibitor SXI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hem-atol 2003 31 686-692. 

There are more than 100 different types of tyrosine kinases present in the body. Sometimes tyrosine kinase inhibitors are referred to as small-molecule inhibitors. Each of the following drugs was developed to block either several or a specific tyrosine kinase. 

As mentioned above, inhibition of adenosine kinase increases extracellular adenosine concentrations. Interest in enhancement of the neuroprotective, antinociceptive, and anti-inflammatory actions of adenosine has encouraged development of systemically applicable adenosine kinase inhibitor drugs. For example, it was found recently that the specific adenosine kinase inhibitor ABT-702, when given intraperitoneally, increases sleep and slow wave EEG activity of rats (Radek et al, 2004), a finding that encourages further research into the hypnogenic effect of this type of drug. 

ScHWOB, E., Bohm, T., Mendenhall, M. D., and Nasmyth, K. The B-type cyclin kinase inhibitor p40SICl controls the Cl to S transition in S. cerevisiae. Cell 1994, 79, 233-44. 

ScHWOB, E., et al.. The B-type cydin kinase inhibitor p40SICl controls the... 

Selective glycogen synthase kinase inhibitors (2004BMCL413), cardiovascular agents (1996JMC2922) and inhibitors of tubulin assembly (1996BCF251, 2000TL5853) of the fused benzoheteropine type have been reported. 

BaselgaJ, HerbstR, LoRussoP, etal. Continuous administration of ZD 1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types evidence of activity and good tolerability. ProcAm Soc Clin Oncol 2000 19 177 (abstr). 

O Hare T, Pollock R, Stoffregen EP et al. Inhibition of wild-type and mutant BCR-ABL by AP23464, a potent ATP-based oncogenie protein kinase inhibitor implications for CML. Blood 2004 104 2532-2539. 

Mazumder A, Gazit A, Levitzki A, Nicklaus M, Yung J, Kohlhagen G, Pommier Y. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochem 1995 34 15111-15122. 

Because of their rapid rate of cell division, cancer cells are also sometimes able to develop drug resistance. Imatinib (4.12) (Figure 4.13) is a kinase inhibitor for the treatment of certain types of leukemia. The x-ray crystal structure of imatinib bound in the active site of the kinase has been solved and shows how mutations in the enzyme interfere with binding and allow drug resistance.20... 

---